NCT07900516
A Prospective, Phase II, Exploratory Study Protocol of a Chemotherapy Sensitivity-based Culmerciclib Combination Regimen in Neoadjuvant Therapy for HR+/HER2- Breast Cancer.
StatusRecruiting
PhasePhase 2
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Study First Submitted
Endpoints
Primary
ORR
Timeframe: up to 18 weeks
Secondary (6)
Change in Ki67 from Baseline to Surgery
Change in Ki67 from Week 2 to Surgery
CCCA
pCR
RCB 0-1
Show 1 moreShow less
Incidence and Severity of AEs/SAEs
Arms and interventions
Adaptive Culmerciclib Neoadjuvant Therapy for HR+/HER2- Breast CancerExperimental
Drugs: Kumoxili, Docetaxel, Epirubicin, Cyclophosphamide, Letrozole, Everolimus (Afinitor®)
Sites
1 site in 1 country
- The First Affiliated Hospital of Nanjing Medical UniversityNanjing, Jiangsu, China